Estimating the Prevalence and Impact of Antidepressant-Induced Sexual Dysfunction in 2 European Countries: A Cross-Sectional Patient Survey.
J Clin Psychiatry 2006;67:204-210
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: Sexual dysfunction is a common side effect of antidepressant treatment, but recognition of the problem is variable. The aim of this stuy was to estimate the prevalence and impact of sexual dysfunction during antidepressant treatment in 2 European countries.
Method: A cross-sectional survey of
502 adults in France and the United Kingdom. All participants were diagnosed with depression
and taking a selective serotonin reuptake
inhibitor (SSRI) or serotonin-norepinephrine reuptake
inhibitor (SNRI), starting within the previous 3 months. Information was gathered about
other medications and conditions known to impair sexual functioning, recent changes in sexual functioning, and the impact of any changes. The Medical Outcomes Study 12-Item
Short-Form Health Survey and the Arizona Sexual
Experience Scale were administered to measure health
status and sexual functioning. Data were collected
from June to July of 2002.
Results: Applying a prevalence estimate
algorithm, 26.6% of the French sample and 39.2% of the U.K. sample were classified as having
antidepressant-induced sexual dysfunction; 34.2%
of men and 32.5% of women were classified with antidepressant-induced sexual dysfunction.
There was no clear pattern of
antidepressant-induced sexual dysfunction related to specific
antidepressants. Patients with antidepressant-induced
sexual dysfunction reported that changes in sexual
functioning negatively affected their self-esteem, mood, and relationships with sexual
partners. 23.8% of the French sample and 25.2% of
the U.K. sample reported that they perceived that their partner was dissatisfied with their sex life.
Conclusion: The prevalence of
antidepressant-induced sexual dysfunction in this study
is similar to previous estimates reported in the literature. The impact of antidepressant-induced sexual dysfunction is substantial
and negatively affects quality of life,
self-esteem, mood, and relationships with sexual partners.